$CATX SEC Filings

Perspective’s [212Pb]Bamzireotide Navoxetan (VMT-α-NET) Demonstrates Encouraging Safety, Durable Disease Control, and Robust Tumor Response Across Multiple Dose Cohorts in Phase 1/2a Trial in Advanced SSTR2-Expressing NETs

Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors

Next-Generation Radiopharmaceuticals Redefining Targeted Oncology

Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors

Sold 80,783 shares ($251K) · Sold 167,149 shares ($526K)

Next-Generation Radiopharmaceuticals Redefining Targeted Oncology

Sold 42,129 shares ($131K)

Sold 78,145 shares ($246K) · Sold 35,769 shares ($112K)

Sold 35,769 shares ($112K)

Sold 78,145 shares ($246K)